kpcczКомплексные проблемы сердечно-сосудистых заболеванийComplex Issues of Cardiovascular Diseases2306-12782587-9537Federal State Budgetary Institution “Research Institute for Complex Issues of Cardiovascular Diseases”10.17802/2306-1278-2020-9-3-69-80kpccz-759Research ArticleАНАЛИТИЧЕСКИЙ ОБЗОРANALYTICAL REVIEWАритмогенные эффекты доксорубицинаArrhythmogenic effects of doxorubicinhttps://orcid.org/0000-0002-2712-0227ЧаулинА. М.ChaulinA. M.

ассистент кафедры гистологии и эмбриологии, ул. Аэродромная, 43, Самара, 443070;

врач клинической лабораторной диагностики клинико-диагностической лаборатории, ул. Чапаевская, 89, Самара, 443099

MD, assistant at the Histology and Embryology Department, 43, Aerodromnaya St., Samara, 443070;

pathologist at the Clinical and Diagnostic Laboratory, 89, Chapayevskaya St., Samara, 443099

alekseymichailovich22976@gmail.comhttps://orcid.org/0000-0002-6453-2976ДупляковД. В.DuplyakovD. V.

доктор медицинских наук, заместитель главного врача по медицинской части, ул. Аэродромная, 43, Самара, 443070;

профессор кафедры кардиологии и сердечно-сосудистой хирургии института профессионального образования, ул. Чапаевская, 89, Самара, 443099

PhD, Deputy Director for Medical Services, 43, Aerodromnaya St., Samara, 443070;

Professor at the Department of Cardiology and Cardiovascular Surgery, 89, Chapayevskaya St., Samara, 443099

Государственное бюджетное учреждение здравоохранения «Самарский областной клинический кардиологический диспансер им. В.П. Полякова»; Федеральное государственное бюджетное образовательное учреждение высшего образования «Самарский государственный медицинский университет» Министерства здравоохранения Российской ФедерацииРоссияSamara Regional Clinical Cardiology Dispensary; Samara State Medical UniversityRussian Federation202028092020936980Copyright © Чаулин А.М., Дупляков Д.В., 20202020Чаулин А.М., Дупляков Д.В.Chaulin A.M., Duplyakov D.V.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.nii-kpssz.com/jour/article/view/759

В статье обсуждаются неблагоприятные аритмогенные эффекты противоопухолевого препарата – доксорубицина. 

Доксорубицин оказывает значимое влияние на потенциал действия и ионные токи кардиомиоцитов, динамику внутриклеточной концентрации кальция.

Онкологические заболевания – одна из ведущих причин смертности и инвалидизации населения. Среди множества доступных на сегодняшний день методов лечения онкопатологий важное место занимает антибиотик антрациклинового ряда – доксорубицин. Однако неблагоприятное сопутствующее воздействие на организм человека, в частности сердечно-сосудистую систему, не позволяет в полной мере использовать противоопухолевые свойства доксорубицина. Кардиотоксичность доксорубицина проявляется в виде электрокардиографических нарушений и аритмий, дегенеративной кардиомиопатии, хронической сердечной недостаточности. В обзоре рассмотрены аритмогенные эффекты доксорубицина: влияние на электрокардиографические показатели, потенциал действия кардиомиоцитов, сердечные ионные токи, динамику внутриклеточной концентрации кальция. Изучение и установление конкретных патофизиологических механизмов аритмогенного действия доксорубицина необходимы для разработки и обоснованного применения кардиопротекторных мероприятий.

The article discusses the adverse arrhythmogenic effects of an antitumor drug – doxorubicin.

Doxorubicin has a significant effect on the action potentials and ion currents of cardiomyocytes, the dynamics of intracellular calcium concentration.

Oncological diseases are the leading causes of death and disability of the population, causing extremely high socio-economic damage. Among the many currently available drugs for the treatment of cancer, an important place is taken by the anthracycline antibiotic – doxorubicin. However, adverse concomitant effects on several organs and systems of the human body, in particular on the cardiovascular system, do not allow the full use of the high potential of doxorubicin`s antitumor effectiveness. Cardiotoxicity of doxorubicin is manifested in the form of electrocardiographic abnormalities and arrhythmias, degenerative cardiomyopathy and chronic heart failure. The authors consider the following arrhythmogenic effects of doxorubicin: the mechanisms of influence of doxorubicin on electrocardiographic parameters, the action potential of cardiomyocytes, cardiac ion currents and the dynamics of intracellular calcium concentration. The study and assessment of specific pathophysiological mechanisms of arrhythmogenic effects of doxorubicin is necessary for the development and justified use of cardioprotective measures.

доксорубицинкальцийнатрийналийпотенциал действиядеполяризацияреполяризацияаритмииактивные формы кислородаdoxorubicincalciumsodiumpotassiumaction potentialdepolarizationrepolarizationarrhythmiasreactive oxygen species (ROS)ReferencesFerlay J., Soerjomataram I., Dikshit R., Eser S., Mathers C., Rebelo M., et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer. 2015; 136 (5): E359-386. doi: 10.1002/ijc.29210.Ferlay J., Soerjomataram I., Dikshit R., Eser S., Mathers C., Rebelo M., et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer. 2015; 136 (5): E359-386. doi: 10.1002/ijc.29210.Tacar O., Sriamornsak P., Dass C.R. Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. The Journal Pharmacy and Pharmacology. 2013; 65 (2): 157-70. doi: 10.1111/j.2042-7158.2012.01567.x.Tacar O., Sriamornsak P., Dass C.R. Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. The Journal Pharmacy and Pharmacology. 2013; 65 (2): 157-70. doi: 10.1111/j.2042-7158.2012.01567.x.Simunek T., Sterba M., Popelova O., Adamcova M., Hrdina R., Gersl V. Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacological Reports. 2009; 61 (1): 154- 71. DOI: 10.1016/s1734-1140(09)70018-0.Simunek T., Sterba M., Popelova O., Adamcova M., Hrdina R., Gersl V. Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacological Reports. 2009; 61 (1): 154- 71. doi: 10.1016/s1734-1140(09)70018-0.Kim S.Y., Kim S.J., Kim B.J., Rah S.Y., Chung S.M., Im M.J., Kim U.H. Doxorubicin-induced reactive oxygen species generation and intracellular Ca2+ increase are reciprocally modulated in rat cardiomyocytes. Experimental & Molecular Medicine. 2006; 38 (5): 535-545. doi: 10.1038/emm.2006.63.Kim S.Y., Kim S.J., Kim B.J., Rah S.Y., Chung S.M., Im M.J., Kim U.H. Doxorubicin-induced reactive oxygen species generation and intracellular Ca2+ increase are reciprocally modulated in rat cardiomyocytes. Experimental & Molecular Medicine. 2006; 38 (5): 535-545. doi: 10.1038/emm.2006.63.Селиверстова Д.В., Евсина О.В. Кардиотоксичность химиотерапии. Сердце: журнал для практикующих врачей. 2016; 15 (1): 50-57. doi: 10.18087/rhj.2016.1.2115Seliverstova D.V., Evsina O.V. Cardiotoxicity of chemotherapy. Russian Heart Journal. 2016; 15 (1): 50-57. doi: 10.18087/rhj.2016.1.2115 (in Russian)Чаулин А.М., Карслян Л.С., Григорьева Е.В., Нурбалтаева Д.А., Дупляков Д.В. Клинико-диагностическая ценность кардиомаркеров в биологических жидкостях человека. Кардиология. 2019; 59 (11): 66-75. doi:10.18087/cardio.2019.11.n414Chaulin A.M., Karslyan L.S., Grigoriyeva E.V., Nurbaltaeva D.A., Duplyakov D.V. Clinical and Diagnostic Value of Cardiac Markers in Human Biological Fluids. Kardiologiia. 2019;59(11):66– 75. doi:10.18087/cardio.2019.11.n414 (in Russian)Jones M., O'Gorman P., Kelly C., Mahon N., Fitzgibbon M.C. High-sensitive cardiac troponin-I facilitates timely detection of subclinical anthracycline-mediated cardiac injury. Annals of Clinical Biochemistry. 2017; 54 (1): 149-157. doi: 10.1177/0004563216650464.Jones M., O'Gorman P., Kelly C., Mahon N., Fitzgibbon M.C. High-sensitive cardiac troponin-I facilitates timely detection of subclinical anthracycline-mediated cardiac injury. Annals of Clinical Biochemistry. 2017; 54 (1): 149-157. doi: 10.1177/0004563216650464.Чаулин АМ, Дупляков ДВ. Повышение кардиальных тропонинов, не ассоциированное с острым коронарным синдромом. Часть 1. Кардиология: новости, мнения, обучение. 2019; 7 (2): 13-23. doi: 10.24411/2309-1908-2019-12002.Chaulin A.M., Duplyakov D.V. Increased cardiac troponins, not associated with acute coronary syndrome. Part 1. Kardiologiya: novosti, mneniya, obuchenie [Cardiology: News, Opinions, Training]. 2019; 7 (2): 13–23. doi: 10.24411/2309-1908-2019-12002. (in Russian)Чаулин АМ, Дупляков ДВ. Повышение кардиальных тропонинов, не ассоциированное с острым коронарным синдромом. Часть 2. Кардиология: новости, мнения, обучение. 2019; 7 (2): 24-35. doi: 10.24411/2309-1908-2019-12003.Chaulin A.M., Duplyakov D.V. Increased cardiac troponins, not associated with acute coronary syndrome. Part 2. Kardiologiya: novosti, mneniya, obuchenie [Cardiology: News, Opinions, Training]. 2019; 7 (2): 24–35. doi: 10.24411/2309-1908-2019-12003. (in Russian)Чаулин А.М., Карслян Л.С., Григорьева Е.В., Нурбалтаева Д.А., Дупляков Д.В. Особенности метаболизма сердечных тропонинов (обзор литературы). Комплексные проблемы сердечно-сосудистых заболеваний. 2019; 8 (4): 103-115. https://doi.org/10.17802/2306-1278-2019-8-4-103- 115.Chaulin A.M., Karslyan L.S., Grigorieva E.V., Nurbaltaeva D.A., Duplyakov D.V. Metabolism of cardiac troponins (literature review). Complex Issues of Cardiovascular Diseases. 2019; 8 (4): 103-115. doi: 10.17802/2306-1278-2019-8-4-103-115 (in Russian)Armstrong G.T., Liu Q., Yasui Y., Neglia J.P., Leisenring W., Robison L.L., Mertens A.C. Late mortality among 5-year survivors of childhood cancer: a summary from the Childhood Cancer Survivor Study. Journal of Clinical Oncology. 2009; 27 (14): 2328-2338. doi:10.1200/jco.2008.21.1425.Armstrong G.T., Liu Q., Yasui Y., Neglia J.P., Leisenring W., Robison L.L., Mertens A.C. Late mortality among 5-year survivors of childhood cancer: a summary from the Childhood Cancer Survivor Study. Journal of Clinical Oncology. 2009; 27 (14): 2328-2338. doi:10.1200/jco.2008.21.1425.Swain S.M., Whaley F.S., Ewer M.S. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003; 97 (11): 2869-2879. DOI: 10.1002/cncr.11407.Swain S.M., Whaley F.S., Ewer M.S. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003; 97 (11): 2869-2879. doi: 10.1002/cncr.11407.Volkova M., Russell R.3rd. Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Current Cardiology Reviews. 2011; 7 (4): 214-220. doi: 10.2174/157340311799960645.Volkova M., Russell R.3rd. Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Current Cardiology Reviews. 2011; 7 (4): 214-220. doi: 10.2174/157340311799960645.Carvalho F.S., Burgeiro A., Garcia R., Moreno A.J., Carvalho R.A., Oliveira P.J. Doxorubicin-induced cardiotoxicity: from bioenergetic failure and cell death to cardiomyopathy. Medical Research Reviews. 2014; 34 (1): 106- 35. doi: 10.1002/med.21280.Carvalho F.S., Burgeiro A., Garcia R., Moreno A.J., Carvalho R.A., Oliveira P.J. Doxorubicin-induced cardiotoxicity: from bioenergetic failure and cell death to cardiomyopathy. Medical Research Reviews. 2014; 34 (1): 106- 35. doi: 10.1002/med.21280.Yin J., Guo J., Zhang Q., Cui L., Zhang L., Zhang T., et al. Doxorubicin-induced mitophagy and mitochondrial damage is associated with dysregulation of the PINK1/parkin pathway. Toxicol In Vitro. 2018; 51: 1-10. doi: 10.1016/j.tiv.2018.05.001.Yin J., Guo J., Zhang Q., Cui L., Zhang L., Zhang T., et al. Doxorubicin-induced mitophagy and mitochondrial damage is associated with dysregulation of the PINK1/parkin pathway. Toxicol In Vitro. 2018; 51: 1-10. doi: 10.1016/j.tiv.2018.05.001.Renu K., V. G. A., P. B. T.P., Arunachalam S. Molecular mechanism of doxorubicin-induced cardiomyopathy - An update. European Journal of Pharmacology. 2018; 818: 241- 253. doi: 10.1016/j.ejphar.2017.10.043.Renu K., V. G. A., P. B. T.P., Arunachalam S. Molecular mechanism of doxorubicin-induced cardiomyopathy - An update. European Journal of Pharmacology. 2018; 818: 241- 253. doi: 10.1016/j.ejphar.2017.10.043.Wagner S., Rokita A.G., Anderson M.E., Maier L.S. Redox regulation of sodium and calcium handling. Antioxidants & Redox Signaling. 2013; 18 (9): 1063-1077. doi: 10.1089/ars.2012.4818.Wagner S., Rokita A.G., Anderson M.E., Maier L.S. Redox regulation of sodium and calcium handling. Antioxidants & Redox Signaling. 2013; 18 (9): 1063-1077. doi: 10.1089/ars.2012.4818.Larsen R.L., Jakacki R.I., Vetter V.L., Meadows A.T., Silber J.H., Barber G. Electrocardiographic changes and arrhythmias after cancer therapy in children and young adults. The American Journal of Cardiology. 1992; 70 (1): 73-77. doi: 10.1016/0002-9149(92)91393-i.Larsen R.L., Jakacki R.I., Vetter V.L., Meadows A.T., Silber J.H., Barber G. Electrocardiographic changes and arrhythmias after cancer therapy in children and young adults. The American Journal of Cardiology. 1992; 70 (1): 73-77. doi: 10.1016/0002-9149(92)91393-i.Kilickap S., Barista I., Akgul E., Aytemir K., Aksoy S., Tekuzman G. Early and late arrhythmogenic effects of doxorubicin. Southern Medical Journal. 2007; 100 (3): 262- 265. doi: 10.1097/01.smj.0000257382.89910.feKilickap S., Barista I., Akgul E., Aytemir K., Aksoy S., Tekuzman G. Early and late arrhythmogenic effects of doxorubicin. Southern Medical Journal. 2007; 100 (3): 262- 265. doi: 10.1097/01.smj.0000257382.89910.feKilickap S., Akgul E., Aksoy S., Aytemir K., Barista I. Doxorubicin-induced second degree and complete atrioventricular block. Europace. 2005; 7 (3): 227-230. doi: 10.1016/j.eupc.2004.12.012Kilickap S., Akgul E., Aksoy S., Aytemir K., Barista I. Doxorubicin-induced second degree and complete atrioventricular block. Europace. 2005; 7 (3): 227-230. doi: 10.1016/j.eupc.2004.12.012Rudzinski T., Ciesielczyk M., Religa W., Bednarkiewicz Z., Krzeminska-Pakula M. Doxorubicin-induced ventricular arrhythmia treated by implantation of an automatic cardioverterdefibrillator. Europace. 2007; 9 (5): 278-280. doi: 10.1093/europace/eum033Rudzinski T., Ciesielczyk M., Religa W., Bednarkiewicz Z., Krzeminska-Pakula M. Doxorubicin-induced ventricular arrhythmia treated by implantation of an automatic cardioverter-defibrillator. Europace. 2007; 9 (5): 278-280. doi: 10.1093/europace/eum033Markman T.M., Ruble K., Loeb D., Chen A., Zhang Y., Beasley G.S., et al. Electrophysiological effects of anthracyclines in adult survivors of pediatric malignancy. Pediatric Blood & Cancer. 2017; 64 (11). doi: 10.1002/pbc.26556Markman T.M., Ruble K., Loeb D., Chen A., Zhang Y., Beasley G.S., et al. Electrophysiological effects of anthracyclines in adult survivors of pediatric malignancy. Pediatric Blood & Cancer. 2017; 64 (11). doi: 10.1002/pbc.26556Amin A.S., Tan H.L., Wilde A.A. Cardiac ion channels in health and disease. Heart Rhythm. 2010; 7 (1): 117-126. doi: 10.1016/j.hrthm.2009.08.005Amin A.S., Tan H.L., Wilde A.A. Cardiac ion channels in health and disease. Heart Rhythm. 2010; 7 (1): 117-126. doi: 10.1016/j.hrthm.2009.08.005Antzelevitch C., Burashnikov A. Overview of Basic Mechanisms of Cardiac Arrhythmia. Cardiac Electrophysiology Clinics. 2011; 3 (1): 23-45. doi: 10.1016/j.ccep.2010.10.012Antzelevitch C., Burashnikov A. Overview of Basic Mechanisms of Cardiac Arrhythmia. Cardiac Electrophysiology Clinics. 2011; 3 (1): 23-45. doi: 10.1016/j.ccep.2010.10.012Killeen M.J., Sabir I.N., Grace A.A., Huang C.L. Dispersions of repolarization and ventricular arrhythmogenesis: lessons from animal models. Progress in Biophysics and Molecular Biology. 2008; 98 (2-3): 219-229. doi: 10.1016/j.pbiomolbio.2008.10.008.Killeen M.J., Sabir I.N., Grace A.A., Huang C.L. Dispersions of repolarization and ventricular arrhythmogenesis: lessons from animal models. Progress in Biophysics and Molecular Biology. 2008; 98 (2-3): 219-229. doi: 10.1016/j.pbiomolbio.2008.10.008.Amioka M., Sairaku A., Ochi T., Okada T., Asaoku H., Kyo T., Kihara Y. Prognostic Significance of New-Onset Atrial Fibrillation in Patients With Non-Hodgkin's Lymphoma Treated With Anthracyclines. The American Journal of Cardiology. 2016; 118 (9): 1386-1389. doi: 10.1016/j.amjcard.2016.07.049Amioka M., Sairaku A., Ochi T., Okada T., Asaoku H., Kyo T., Kihara Y. Prognostic Significance of New-Onset Atrial Fibrillation in Patients With Non-Hodgkin's Lymphoma Treated With Anthracyclines. The American Journal of Cardiology. 2016; 118 (9): 1386-1389. doi: 10.1016/j.amjcard.2016.07.049Purohit A., Rokita A.G., Guan X., Chen B., Koval O.M., Voigt N.. et al. Oxidized Ca(2+)/calmodulin-dependent protein kinase II triggers atrial fibrillation. Circulation. 2013; 128 (16): 1748-1757. doi:10.1161/circulationaha.113.003313.Purohit A., Rokita A.G., Guan X., Chen B., Koval O.M., Voigt N.. et al. Oxidized Ca(2+)/calmodulin-dependent protein kinase II triggers atrial fibrillation. Circulation. 2013; 128 (16): 1748-1757. doi:10.1161/circulationaha.113.003313.Nousiainen T., Vanninen E., Rantala A., Jantunen E., Hartikainen J. QT dispersion and late potentials during doxorubicin therapy for non-Hodgkin's lymphoma. Journal of Internal Medicine. 1999; 245 (4): 359-364. doi: 10.1046/j.1365-2796.1999.00480.x.Nousiainen T., Vanninen E., Rantala A., Jantunen E., Hartikainen J. QT dispersion and late potentials during doxorubicin therapy for non-Hodgkin's lymphoma. Journal of Internal Medicine. 1999; 245 (4): 359-364. doi: 10.1046/j.1365-2796.1999.00480.x.Horacek J.M., Jakl M., Horackova J., Pudil R., Jebavy L., Maly J. Assessment of anthracycline-induced cardiotoxicity with electrocardiography. Experimental Oncology. 2009; 31 (2): 115-117. doi: https://www.ncbi.nlm.nih.gov/pubmed/19550402Horacek J.M., Jakl M., Horackova J., Pudil R., Jebavy L., Maly J. Assessment of anthracycline-induced cardiotoxicity with electrocardiography. Experimental Oncology. 2009; 31 (2): 115-117. doi: https://www.ncbi.nlm.nih.gov/pubmed/19550402Veronese P., Hachul D.T., Scanavacca M.I., Hajjar L.A., Wu T.C., Sacilotto L., et al. Effects of anthracycline, cyclophosphamide and taxane chemotherapy on QTc measurements in patients with breast cancer. PLoS One. 2018; 13 (5): e0196763. doi: 10.1371/journal.pone.0196763Veronese P., Hachul D.T., Scanavacca M.I., Hajjar L.A., Wu T.C., Sacilotto L., et al. Effects of anthracycline, cyclophosphamide and taxane chemotherapy on QTc measurements in patients with breast cancer. PLoS One. 2018; 13 (5): e0196763. doi: 10.1371/journal.pone.0196763Sarubbi B., Orditura M., Ducceschi V., De Vita F., Santangelo L., Ciaramella F., et al. Ventricular repolarization time indexes following anthracycline treatment. Heart and Vessels. 1997; 12 (6): 262-266. doi: 10.1007/bf02766801Sarubbi B., Orditura M., Ducceschi V., De Vita F., Santangelo L., Ciaramella F., et al. Ventricular repolarization time indexes following anthracycline treatment. Heart and Vessels. 1997; 12 (6): 262-266. doi: 10.1007/bf02766801Jensen R.A., Acton E.M., Peters J.H. Doxorubicin cardiotoxicity in the rat: comparison of electrocardiogram, transmembrane potential, and structural effects. Journal of Cardiovascular Pharmacology. 1984; 6 (1): 186-200. doi: https://www.ncbi.nlm.nih.gov/pubmed/6199603Jensen R.A., Acton E.M., Peters J.H. Doxorubicin cardiotoxicity in the rat: comparison of electrocardiogram, transmembrane potential, and structural effects. Journal of Cardiovascular Pharmacology. 1984; 6 (1): 186-200. doi: https://www.ncbi.nlm.nih.gov/pubmed/6199603Milberg P., Fleischer D., Stypmann J., Osada N., Monnig G., Engelen M.A., et al. Reduced repolarization reserve due to anthracycline therapy facilitates torsade de pointes induced by IKr blockers. Basic Research in Cardiology. 2007; 102 (1): 42- 51. doi: 10.1007/s00395-006-0609-0Milberg P., Fleischer D., Stypmann J., Osada N., Monnig G., Engelen M.A., et al. Reduced repolarization reserve due to anthracycline therapy facilitates torsade de pointes induced by IKr blockers. Basic Research in Cardiology. 2007; 102 (1): 42- 51. doi: 10.1007/s00395-006-0609-0Ducroq J., Moha ou Maati H., Guilbot S., Dilly S., Laemmel E., Pons-Himbert C., et al. Dexrazoxane protects the heart from acute doxorubicin-induced QT prolongation: a key role for I(Ks). British Journal of Pharmacology. 2010; 159 (1): 93-101. doi: 10.1111/j.1476-5381.2009.00371.xDucroq J., Moha ou Maati H., Guilbot S., Dilly S., Laemmel E., Pons-Himbert C., et al. Dexrazoxane protects the heart from acute doxorubicin-induced QT prolongation: a key role for I(Ks). British Journal of Pharmacology. 2010; 159 (1): 93-101. doi: 10.1111/j.1476-5381.2009.00371.xKharin S., Krandycheva V., Tsvetkova A., Strelkova M., Shmakov D. Remodeling of ventricular repolarization in a chronic doxorubicin cardiotoxicity rat model. Fundamental & Clinical Pharmacology. 2013; 27 (4): 364-372. doi: 10.1111/j.1472-8206.2012.01037.xKharin S., Krandycheva V., Tsvetkova A., Strelkova M., Shmakov D. Remodeling of ventricular repolarization in a chronic doxorubicin cardiotoxicity rat model. Fundamental & Clinical Pharmacology. 2013; 27 (4): 364-372. doi: 10.1111/j.1472-8206.2012.01037.xAgen C., Bernardini N., Danesi R., Della Torre P., Costa M., Del Tacca M. Reducing doxorubicin cardiotoxicity in the rat using deferred treatment with ADR-529. Cancer Chemotherapy and Pharmacology. 1992; 30 (2): 95-99. doi: 10.1007/bf00686399Agen C., Bernardini N., Danesi R., Della Torre P., Costa M., Del Tacca M. Reducing doxorubicin cardiotoxicity in the rat using deferred treatment with ADR-529. Cancer Chemotherapy and Pharmacology. 1992; 30 (2): 95-99. doi: 10.1007/bf00686399He L., Xiao J., Fu H., Du G., Xiao X., Zhang C., et al. Effect of oxidative stress on ventricular arrhythmia in rabbits with adriamycin-induced cardiomyopathy. Journal of Huazhong University of Science and Technology. Medical Sciences. 2012; 32 (3): 334-339. doi: 10.1007/s11596-012-0058-yHe L., Xiao J., Fu H., Du G., Xiao X., Zhang C., et al. Effect of oxidative stress on ventricular arrhythmia in rabbits with adriamycin-induced cardiomyopathy. Journal of Huazhong University of Science and Technology. Medical Sciences. 2012; 32 (3): 334-339. doi: 10.1007/s11596-012-0058-yPye M.P., Cobbe S.M. Arrhythmogenesis in experimental models of heart failure: the role of increased load. Cardiovascular Research. 1996; 32 (2): 248-257. doi: 10.1016/0008-6363(96)00080-6Pye M.P., Cobbe S.M. Arrhythmogenesis in experimental models of heart failure: the role of increased load. Cardiovascular Research. 1996; 32 (2): 248-257. doi: 10.1016/0008-6363(96)00080-6Pecoraro M., Rodríguez-Sinovas A., Marzocco S., Ciccarelli M., Iaccarino G., Pinto A., Popolo A. Cardiotoxic Effects of Short-Term Doxorubicin Administration: Involvement of Connexin 43 in Calcium Impairment. International Journal of Molecular Sciences. 2017; 18 (10). pii: E2121. doi: 10.3390/ijms18102121.Pecoraro M., Rodríguez-Sinovas A., Marzocco S., Ciccarelli M., Iaccarino G., Pinto A., Popolo A. Cardiotoxic Effects of Short-Term Doxorubicin Administration: Involvement of Connexin 43 in Calcium Impairment. International Journal of Molecular Sciences. 2017; 18 (10). pii: E2121. doi: 10.3390/ijPoelzing S., Rosenbaum D.S. Altered connexin43 expression produces arrhythmia substrate in heart failure. American Journal of Physiology. Heart and Circulatory Physiology. 2004; 287 (4): H1762-1770. doi: 10.1152/ajpheart.00346.2004Poelzing S., Rosenbaum D.S. Altered connexin43 expression produces arrhythmia substrate in heart failure. American Journal of Physiology. Heart and Circulatory Physiology. 2004; 287 (4): H1762-1770. doi: 10.1152/ajpheart.00346.2004Xin Y., Zhang S., Gu L., Liu S., Gao H., You Z., et al. Electrocardiographic and biochemical evidence for the cardioprotective effect of antioxidants in acute doxorubicininduced cardiotoxicity in the beagle dogs. Biological & Pharmaceutical Bulletin. 2011; 34 (10): 1523-1526. doi: 10.1248/bpb.34.1523Xin Y., Zhang S., Gu L., Liu S., Gao H., You Z., et al. Electrocardiographic and biochemical evidence for the cardioprotective effect of antioxidants in acute doxorubicininduced cardiotoxicity in the beagle dogs. Biological & Pharmaceutical Bulletin. 2011; 34 (10): 1523-1526. doi: 10.1248/bpb.34.1523Wu Y., Anderson M.E. CaMKII in sinoatrial node physiology and dysfunction. Frontiers in Pharmacology. 2014; 5: 48. doi: 10.3389/fphar.2014.00048Wu Y., Anderson M.E. CaMKII in sinoatrial node physiology and dysfunction. Frontiers in Pharmacology. 2014; 5: 48. doi: 10.3389/fphar.2014.00048Sag C.M., Kohler A.C., Anderson M.E., Backs J., Maier L.S. CaMKII-dependent SR Ca leak contributes to doxorubicininduced impaired Ca handling in isolated cardiac myocytes. Journal of Molecular and Cellular Cardiology. 2011; 51 (5): 749-759. doi: 10.1016/j.yjmcc.2011.07.016Sag C.M., Kohler A.C., Anderson M.E., Backs J., Maier L.S. CaMKII-dependent SR Ca leak contributes to doxorubicininduced impaired Ca handling in isolated cardiac myocytes. Journal of Molecular and Cellular Cardiology. 2011; 51 (5): 749-759. doi: 10.1016/j.yjmcc.2011.07.016Tscheschner H., Meinhardt E., Schlegel P., Jungmann A., Lehmann L.H., Muller O.J., et al. CaMKII activation participates in doxorubicin cardiotoxicity and is attenuated by moderate GRP78 overexpression. PLoS One. 2019; 14 (4): e0215992. doi: 10.1371/journal.pone.0215992.Tscheschner H., Meinhardt E., Schlegel P., Jungmann A., Lehmann L.H., Muller O.J., et al. CaMKII activation participates in doxorubicin cardiotoxicity and is attenuated by moderate GRP78 overexpression. PLoS One. 2019; 14 (4): e0215992. doi: 10.1371/journal.pone.0215992.Xie L.H., Chen F., Karagueuzian H.S., Weiss J.N. Oxidative-stress-induced afterdepolarizations and calmodulin kinase II signaling. Circulation Research. 2009; 104 (1): 79-86. doi: 10.1161/CIRCRESAHA.108.183475Xie L.H., Chen F., Karagueuzian H.S., Weiss J.N. Oxidative-stress-induced afterdepolarizations and calmodulin kinase II signaling. Circulation Research. 2009; 104 (1): 79-86. doi: 10.1161/CIRCRESAHA.108.183475Venditti P., Balestrieri M., De Leo T., Di Meo S. Free radical involvement in doxorubicin-induced electrophysiological alterations in rat papillary muscle fibres. Cardiovasc Res. 1998; 38 (3): 695-702. doi: 10.1016/s0008-6363(98)00034-0Venditti P., Balestrieri M., De Leo T., Di Meo S. Free radical involvement in doxorubicin-induced electrophysiological alterations in rat papillary muscle fibres. Cardiovasc Res. 1998; 38 (3): 695-702. doi: 10.1016/s0008-6363(98)00034-0Lazarus M.L., Rossner K.L., Anderson K.M. Adriamycin-induced alterations of the action potential in rat papillary muscle. Cardiovascular Research. 1980; 14 (8): 446- 450. doi: 10.1093/cvr/14.8.446Lazarus M.L., Rossner K.L., Anderson K.M. Adriamycin-induced alterations of the action potential in rat papillary muscle. Cardiovascular Research. 1980; 14 (8): 446- 450. doi: 10.1093/cvr/14.8.446Wang Y.X., Korth M. Effects of doxorubicin on excitation-contraction coupling in guinea pig ventricular myocardium. Circulation Research. 1995; 76 (4): 645-653. doi: 10.1161/01.res.76.4.645Wang Y.X., Korth M. Effects of doxorubicin on excitation-contraction coupling in guinea pig ventricular myocardium. Circulation Research. 1995; 76 (4): 645-653. doi: 10.1161/01.res.76.4.645Shenasa H., Calderone A., Vermeulen M., Paradis P., Stephens H., Cardinal R., et al. Chronic doxorubicin induced cardiomyopathy in rabbits: mechanical, intracellular action potential, and beta adrenergic characteristics of the failing myocardium. Cardiovascular Research. 1990; 24 (7): 591-604. doi: 10.1093/cvr/24.7.591Shenasa H., Calderone A., Vermeulen M., Paradis P., Stephens H., Cardinal R., et al. Chronic doxorubicin induced cardiomyopathy in rabbits: mechanical, intracellular action potential, and beta adrenergic characteristics of the failing myocardium. Cardiovascular Research. 1990; 24 (7): 591-604. doi: 10.1093/cvr/24.7.591Binah O., Cohen I.S., Rosen M.R. The effects of adriamycin on normal and ouabain-toxic canine Purkinje and ventricular muscle fibers. Circulation Research. 1983; 53 (5): 655-662. doi: 10.1161/01.res.53.5.655Binah O., Cohen I.S., Rosen M.R. The effects of adriamycin on normal and ouabain-toxic canine Purkinje and ventricular muscle fibers. Circulation Research. 1983; 53 (5): 655-662. doi: 10.1161/01.res.53.5.655Earm Y.E., Ho W.K., So I. Effects of adriamycin on ionic currents in single cardiac myocytes of the rabbit. Journal of Molecular and Cellular Cardiology. 1994; 26 (2): 163-172. doi: 10.1006/jmcc.1994.1019Earm Y.E., Ho W.K., So I. Effects of adriamycin on ionic currents in single cardiac myocytes of the rabbit. Journal of Molecular and Cellular Cardiology. 1994; 26 (2): 163-172. doi: 10.1006/jmcc.1994.1019Boucek R.J. Jr., Olson R.D., Brenner D.E., Ogunbunmi E.M., Inui M., Fleischer S. The major metabolite of doxorubicin is a potent inhibitor of membrane-associated ion pumps. A correlative study of cardiac muscle with isolated membrane fractions. The Journal of Biological Chemistry. 1987; 262 (33): 15851-15856. doi: https://www.ncbi.nlm.nih.gov/pubmed/2890636Boucek R.J. Jr., Olson R.D., Brenner D.E., Ogunbunmi E.M., Inui M., Fleischer S. The major metabolite of doxorubicin is a potent inhibitor of membrane-associated ion pumps. A correlative study of cardiac muscle with isolated membrane fractions. The Journal of Biological Chemistry. 1987; 262 (33): 15851-15856. doi: https://www.ncbi.nlm.nih.gov/pubmed/2890636Keung E.C., Toll L., Ellis M., Jensen R.A. L-type cardiac calcium channels in doxorubicin cardiomyopathy in rats morphological, biochemical, and functional correlations. The Journal of Clinical Investigation. 1991; 87 (6): 2108-2113. doi: 10.1172/JCI115241Keung E.C., Toll L., Ellis M., Jensen R.A. L-type cardiac calcium channels in doxorubicin cardiomyopathy in rats morphological, biochemical, and functional correlations. The Journal of Clinical Investigation. 1991; 87 (6): 2108-2113. doi: 10.1172/JCI115241Liang H., Li X., Li S., Zheng M.Q., Rozanski G.J. Oxidoreductase regulation of Kv currents in rat ventricle. Journal of Molecular and Cellular Cardiology. 2008; 44 (6): 1062-1071. doi: 10.1016/j.yjmcc.2008.03.011.Liang H., Li X., Li S., Zheng M.Q., Rozanski G.J. Oxidoreductase regulation of Kv currents in rat ventricle. Journal of Molecular and Cellular Cardiology. 2008; 44 (6): 1062-1071. doi: 10.1016/j.yjmcc.2008.03.011.Hanna A.D., Lam A., Tham S., Dulhunty A.F., Beard N.A. Adverse effects of doxorubicin and its metabolic product on cardiac RyR2 and SERCA2A. Molecular Pharmacology. 2014; 86 (4): 438-449. doi: 10.1124/mol.114.093849Hanna A.D., Lam A., Tham S., Dulhunty A.F., Beard N.A. Adverse effects of doxorubicin and its metabolic product on cardiac RyR2 and SERCA2A. Molecular Pharmacology. 2014; 86 (4): 438-449. doi: 10.1124/mol.114.093849Dolphin A.C. Voltage-gated calcium channels and their auxiliary subunits: physiology and pathophysiology and pharmacology. The Journal of Physiology. 2016; 594 (19): 5369-5390. doi:10.1113/jp272262Dolphin A.C. Voltage-gated calcium channels and their auxiliary subunits: physiology and pathophysiology and pharmacology. The Journal of Physiology. 2016; 594 (19): 5369-5390. doi:10.1113/jp272262Song Y., Shryock J.C., Wagner S., Maier L.S., Belardinelli L. Blocking late sodium current reduces hydrogen peroxideinduced arrhythmogenic activity and contractile dysfunction. The Journal of Pharmacology and Experimental Therapeutics. 2006; 318 (1): 214-222. doi: 10.1124/jpet.106.101832Song Y., Shryock J.C., Wagner S., Maier L.S., Belardinelli L. Blocking late sodium current reduces hydrogen peroxideinduced arrhythmogenic activity and contractile dysfunction. The Journal of Pharmacology and Experimental Therapeutics. 2006; 318 (1): 214-222. doi: 10.1124/jpet.106.101832Wagner S., Ruff H.M., Weber S.L., Bellmann S., Sowa T., Schulte T., et al. Reactive oxygen species-activated Ca/ calmodulin kinase IIδ is required for late I(Na) augmentation leading to cellular Na and Ca overload. Circulation Research. 2011; 108 (5): 555-65. doi: 10.1161/CIRCRESAHA.110.221911Wagner S., Ruff H.M., Weber S.L., Bellmann S., Sowa T., Schulte T., et al. Reactive oxygen species-activated Ca/ calmodulin kinase IIδ is required for late I(Na) augmentation leading to cellular Na and Ca overload. Circulation Research. 2011; 108 (5): 555-65. doi: 10.1161/CIRCRESAHA.110.221911Bers D.M. Cardiac excitation-contraction coupling. Nature. 2002; 415 (6868): 198-205. doi: 10.1038/415198aBers D.M. Cardiac excitation-contraction coupling. Nature. 2002; 415 (6868): 198-205. doi: 10.1038/415198aLlach A., Mazevet M., Mateo P., Villejouvert O., Ridoux A., Rucker-Martin C., et al. Progression of excitationcontraction coupling defects in doxorubicin cardiotoxicity. Journal of Molecular and Cellular Cardiology. 2019; 126: 129- 39. doi:10.1016/j.yjmcc.2018.11.019.Llach A., Mazevet M., Mateo P., Villejouvert O., Ridoux A., Rucker-Martin C., et al. Progression of excitationcontraction coupling defects in doxorubicin cardiotoxicity. Journal of Molecular and Cellular Cardiology. 2019; 126: 129- 39. doi:10.1016/j.yjmcc.2018.11.019.Olson R.D., Gambliel H.A., Vestal R.E., Shadle S.E., Charlier H.A. Jr., Cusack B.J. Doxorubicin cardiac dysfunction: effects on calcium regulatory proteins, sarcoplasmic reticulum, and triiodothyronine. Cardiovasc Toxicol. 2005; 5 (3): 269-83. doi: 10.1385/ct:5:3:269Olson R.D., Gambliel H.A., Vestal R.E., Shadle S.E., Charlier H.A. Jr., Cusack B.J. Doxorubicin cardiac dysfunction: effects on calcium regulatory proteins, sarcoplasmic reticulum, and triiodothyronine. Cardiovasc Toxicol. 2005; 5 (3): 269-83. doi: 10.1385/ct:5:3:269Wagner S., Maier L.S., Bers D.M. Role of sodium and calcium dysregulation in tachyarrhythmias in sudden cardiac death. Circulation Research. 2015; 116 (12): 1956-1970. doi:10.1161/circresaha.116.304678.Wagner S., Maier L.S., Bers D.M. Role of sodium and calcium dysregulation in tachyarrhythmias in sudden cardiac death. Circulation Research. 2015; 116 (12): 1956-1970. doi:10.1161/circresaha.116.304678.Koval O.M., Guan X., Wu Y., Joiner M.L., Gao Z., Chen B. et al. CaV1.2 beta-subunit coordinates CaMKIItriggered cardiomyocyte death and afterdepolarizations. Proc. Natl. Acad. Sci U S A. 2010; 107 (11): 4996-5000. doi:10.1073/pnas.0913760107.Koval O.M., Guan X., Wu Y., Joiner M.L., Gao Z., Chen B. et al. CaV1.2 beta-subunit coordinates CaMKIItriggered cardiomyocyte death and afterdepolarizations. Proc. Natl. Acad. Sci U S A. 2010; 107 (11): 4996-5000. doi:10.1073/ pnas.0913760107.

The authors declare that there are no conflicts of interest present.